Dongsung Pharm (002210) - Net Assets

Latest as of June 2025: ₩40.55 Billion KRW ≈ $27.48 Million USD

Based on the latest financial reports, Dongsung Pharm (002210) has net assets worth ₩40.55 Billion KRW (≈ $27.48 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩147.95 Billion ≈ $100.26 Million USD) and total liabilities (₩107.40 Billion ≈ $72.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Dongsung Pharm (002210) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩40.55 Billion
% of Total Assets	27.41%
Annual Growth Rate	-1.28%
5-Year Change	0.42%
10-Year Change	-8.34%
Growth Volatility	16.77

Dongsung Pharm - Net Assets Trend (2008–2024)

This chart illustrates how Dongsung Pharm's net assets have evolved over time, based on quarterly financial data. Also explore 002210 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Dongsung Pharm (2008–2024)

The table below shows the annual net assets of Dongsung Pharm from 2008 to 2024. For live valuation and market cap data, see how much is Dongsung Pharm worth.

Year	Net Assets	Change
2024-12-31	₩55.18 Billion ≈ $37.39 Million	+38.63%
2023-12-31	₩39.80 Billion ≈ $26.97 Million	-7.02%
2022-12-31	₩42.81 Billion ≈ $29.01 Million	-7.82%
2021-12-31	₩46.44 Billion ≈ $31.47 Million	-15.48%
2020-12-31	₩54.95 Billion ≈ $37.24 Million	-21.61%
2019-12-31	₩70.10 Billion ≈ $47.50 Million	+21.94%
2018-12-31	₩57.48 Billion ≈ $38.96 Million	-10.56%
2017-12-31	₩64.27 Billion ≈ $43.56 Million	+15.55%
2016-12-31	₩55.62 Billion ≈ $37.69 Million	-7.61%
2011-12-31	₩60.20 Billion ≈ $40.80 Million	+1.86%
2010-12-31	₩59.10 Billion ≈ $40.05 Million	-13.05%
2009-12-31	₩67.97 Billion ≈ $46.06 Million	+0.22%
2008-12-31	₩67.82 Billion ≈ $45.96 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Dongsung Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 127.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	₩60.55 Billion	109.74%
Total Equity	₩55.18 Billion	100.00%

Dongsung Pharm Competitors by Market Cap

The table below lists competitors of Dongsung Pharm ranked by their market capitalization.

Company	Market Cap
BELLINI NAUTICA S.P.A. F:F2F	$16.10 Million
HYTN INNOVATIONS INC. F:85W0	$16.10 Million
Mon Courtier Energie Groupe SA PA:ALMCE	$16.10 Million
Oceanic Beverages Co Inc TW:1213	$16.11 Million
Wang-Zheng Bhd KLSE:7203	$16.08 Million
HM Inwest S.A. WAR:HMI	$16.07 Million
Voltaic Strategic Resources Ltd AU:VSR	$16.06 Million
Equus Total Return Closed Fund NYSE:EQS	$16.06 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Dongsung Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 39,802,313,750 to 55,178,210,280, a change of 15,375,896,530 (38.6%).
Net loss of 7,253,006,350 reduced equity.
Other factors increased equity by 22,628,902,880.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-7.25 Billion	-13.14%
Other Changes	₩22.63 Billion	+41.01%
Total Change	₩-	38.63%

Book Value vs Market Value Analysis

This analysis compares Dongsung Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.40x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩2883.85	₩973.00	x
2018-12-31	₩2579.35	₩973.00	x
2019-12-31	₩2970.19	₩973.00	x
2020-12-31	₩2344.40	₩973.00	x
2021-12-31	₩2008.41	₩973.00	x
2022-12-31	₩1872.18	₩973.00	x
2023-12-31	₩1740.68	₩973.00	x
2024-12-31	₩2413.11	₩973.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Dongsung Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -13.14%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -8.20%
• Asset Turnover: 0.58x
• Equity Multiplier: 2.75x
Recent ROE (-13.14%) is below the historical average (-6.75%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	5.39%	5.88%	0.50x	1.84x	₩-3.13 Billion
2009	0.84%	0.83%	0.54x	1.88x	₩-6.23 Billion
2010	-13.29%	-10.92%	0.56x	2.16x	₩-13.76 Billion
2011	2.83%	2.17%	0.63x	2.07x	₩-4.32 Billion
2016	-2.99%	-2.08%	0.64x	2.25x	₩-7.22 Billion
2017	-0.31%	-0.24%	0.66x	1.93x	₩-6.63 Billion
2018	-9.99%	-6.25%	0.66x	2.44x	₩-11.49 Billion
2019	-11.96%	-9.69%	0.66x	1.88x	₩-15.40 Billion
2020	-25.62%	-16.04%	0.70x	2.29x	₩-19.57 Billion
2021	-9.29%	-5.11%	0.81x	2.25x	₩-8.96 Billion
2022	-4.96%	-2.27%	0.87x	2.52x	₩-6.40 Billion
2023	-5.21%	-2.34%	0.77x	2.89x	₩-6.05 Billion
2024	-13.14%	-8.20%	0.58x	2.75x	₩-12.77 Billion

Industry Comparison

This section compares Dongsung Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $401,390,357,055
Average return on equity (ROE) among peers: 0.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Dongsung Pharm (002210)	₩40.55 Billion	5.39%	2.65x	$16.09 Million
Dongwha Pharm.Co.Ltd (000020)	$252.93 Billion	10.38%	0.28x	$113.83 Million
Yuhan Corp. (000100)	$407.93 Billion	10.79%	0.55x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	2.42%	0.28x	$59.61 Million
Yuyu Pharma (000220)	$69.50 Billion	3.97%	0.28x	$46.55 Million
Yuyu Pharma Inc (000225)	$117.04 Billion	1.10%	0.32x	$17.67 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$76.14 Million
Samil Pharm (000520)	$127.83 Billion	1.30%	1.90x	$127.90 Million
Donga Socio Holdings (000640)	$875.86 Billion	17.02%	0.60x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Dongsung Pharm

KO:002210 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$16.09 Million

₩23.75 Billion KRW

Market Cap Rank

#25660 Global

#1917 in Korea

Share Price

₩973.00

Change (1 day)

+0.00%

52-Week Range

₩973.00 - ₩2780.00

All Time High

₩45800.00